ECSP20033467A - Compuestos macrocíclicos para tratar enfermedades - Google Patents

Compuestos macrocíclicos para tratar enfermedades

Info

Publication number
ECSP20033467A
ECSP20033467A ECSENADI202033467A ECDI202033467A ECSP20033467A EC SP20033467 A ECSP20033467 A EC SP20033467A EC SENADI202033467 A ECSENADI202033467 A EC SENADI202033467A EC DI202033467 A ECDI202033467 A EC DI202033467A EC SP20033467 A ECSP20033467 A EC SP20033467A
Authority
EC
Ecuador
Prior art keywords
treat diseases
macrocyclic compounds
cancer
methods
present disclosure
Prior art date
Application number
ECSENADI202033467A
Other languages
English (en)
Inventor
Han Zhang
Jingrong Jean Cui
Jeffrey Whitten
Jane Ung
Evan W Rogers
Dayong Zhai
Wei Deng
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of ECSP20033467A publication Critical patent/ECSP20033467A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción se refiere a ciertos derivados macrocíclicos, las composiciones farmacéuticas que los contienen y los métodos para usarlos para tratar enfermedades, como el cáncer.
ECSENADI202033467A 2017-12-19 2020-06-19 Compuestos macrocíclicos para tratar enfermedades ECSP20033467A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607528P 2017-12-19 2017-12-19
US201862727124P 2018-09-05 2018-09-05
US201862779283P 2018-12-13 2018-12-13

Publications (1)

Publication Number Publication Date
ECSP20033467A true ECSP20033467A (es) 2020-09-30

Family

ID=66992951

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202033467A ECSP20033467A (es) 2017-12-19 2020-06-19 Compuestos macrocíclicos para tratar enfermedades

Country Status (28)

Country Link
US (3) US10745416B2 (es)
EP (2) EP3728271B1 (es)
JP (2) JP7194188B2 (es)
KR (1) KR102814342B1 (es)
CN (1) CN111511746B (es)
AU (1) AU2018392332B2 (es)
BR (1) BR112020012319A2 (es)
CA (1) CA3083674A1 (es)
CL (1) CL2020001632A1 (es)
DK (1) DK3728271T3 (es)
EC (1) ECSP20033467A (es)
ES (1) ES2929467T3 (es)
HR (1) HRP20221502T1 (es)
HU (1) HUE060711T2 (es)
IL (1) IL275265B2 (es)
JO (1) JOP20200152A1 (es)
LT (1) LT3728271T (es)
MX (1) MX2020006490A (es)
PE (1) PE20200937A1 (es)
PH (1) PH12020550901A1 (es)
PL (1) PL3728271T3 (es)
PT (1) PT3728271T (es)
RS (1) RS63787B1 (es)
SG (1) SG11202005590PA (es)
SI (1) SI3728271T1 (es)
SM (1) SMT202200443T1 (es)
TW (1) TW201930312A (es)
WO (1) WO2019126121A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3371171B1 (en) 2015-11-02 2023-10-25 Blueprint Medicines Corporation Inhibitors of ret
IL295978B2 (en) 2017-10-18 2024-01-01 Incyte Corp Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
US10662172B2 (en) 2017-12-19 2020-05-26 Bristol-Myers Squibb Company Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
CN111511746B (zh) * 2017-12-19 2024-01-09 特普医药公司 用于治疗疾病的巨环化合物
BR112020020273A2 (pt) 2018-04-03 2021-04-06 Blueprint Medicines Corporation Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret
WO2020033838A2 (en) 2018-08-10 2020-02-13 Blueprint Medicines Corporation Treatment of egfr-mutant cancer
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
DK3870579T3 (da) 2018-10-22 2025-01-02 Alumis Inc Tyk2-inhibitorer og anvendelser deraf
KR20220046549A (ko) * 2019-06-19 2022-04-14 터닝 포인트 테라퓨틱스, 인크. 거대고리 카이네이스 억제제의 다형체
WO2020257189A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for treating disease
WO2020257165A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for use in treating disease
WO2021027503A1 (zh) * 2019-08-12 2021-02-18 罗欣药业(上海)有限公司 三环类化合物、其制备方法、中间体及应用
CN114929710B (zh) * 2019-12-03 2024-03-29 特普医药公司 用于治疗疾病的巨环
EP4157829A1 (en) 2020-05-29 2023-04-05 Blueprint Medicines Corporation Solid forms of pralsetinib
CN113754682B (zh) 2020-06-04 2023-01-06 赛诺哈勃药业（成都）有限公司 具有大环结构的化合物及其用途
JP2023538517A (ja) 2020-08-05 2023-09-08 シーフォー セラピューティクス， インコーポレイテッド Ｒｅｔの標的分解のための化合物
CN116635076A (zh) * 2020-12-17 2023-08-22 荣山医药股份有限公司 大环化合物及其用途
WO2023060022A1 (en) * 2021-10-05 2023-04-13 Turning Point Therapeutics, Inc. Synthesis of macrocyclic compounds
WO2024017380A1 (zh) * 2022-07-22 2024-01-25 南京明德新药研发有限公司 含三并环的大环类化合物及其应用
WO2024040131A1 (en) * 2022-08-17 2024-02-22 Treeline Biosciences, Inc. Pyridopyrimidine kras inhibitors
JP7571173B2 (ja) 2023-02-24 2024-10-22 キヤノン株式会社 撮像装置、撮像装置の制御方法、及びプログラム

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0690843T3 (da) * 1993-03-25 2000-11-13 Upjohn Co Fornyl- eller cyanosubstituerede indolderivater med dopaninerg aktivitet
CA2137203C (en) 1993-12-07 2006-11-28 William Francis Heath Jr. Protein kinase c inhibitors
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
CA2431187A1 (en) 2000-12-08 2002-06-13 Ortho-Mcneil Pharmaceutical, Inc. Macroheterocylic compounds useful as kinase inhibitors
AU2009288021B2 (en) 2008-09-08 2015-06-18 Merck Patent Gmbh Macrocyclics pyrimidines as Aurora kinase inhibitors
DK2350075T3 (da) 2008-09-22 2014-05-26 Array Biopharma Inc Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer
PT3106463T (pt) 2008-10-22 2018-05-18 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk
RU2539568C2 (ru) 2008-10-31 2015-01-20 Дженентек, Инк. Пиразолопиримидиновые соединения-ингибиторы jak и способы
NZ598766A (en) 2009-10-13 2013-09-27 Elanco Animal Health Ireland Macrocyclic integrase inhibitors
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
RU2735545C2 (ru) 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Макроциклические соединения в качестве ингибиторов киназы trk
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
CA2817785A1 (en) * 2010-11-19 2012-05-24 Toby Blench Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
AU2012299218A1 (en) 2011-08-19 2014-02-20 Merck Sharp & Dohme Corp. Crystal forms of a HCV protease inhibitor
DK2760867T3 (en) 2011-09-30 2016-04-11 Oncodesign Sa Macrocyclic FLT3 kinase inhibitors
LT2822953T (lt) 2012-03-06 2017-04-10 Pfizer Inc. Makrocikliniai dariniai, skirti proliferacinių ligų gydymui
US8969565B2 (en) 2012-03-09 2015-03-03 Lexicon Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use
CN104302649B (zh) 2012-03-09 2017-06-23 莱西肯医药有限公司 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
HRP20191283T1 (hr) * 2014-01-24 2019-10-18 Turning Point Therapeutics, Inc. Diaril makrocikli kao modulatori protein kinaze
EP3172213B1 (en) * 2014-07-21 2021-09-22 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
EP4397665A3 (en) 2015-07-06 2024-08-21 Turning Point Therapeutics, Inc. Diaryl macrocycle polymorph
DK3325488T3 (da) 2015-07-21 2020-09-14 Turning Point Therapeutics Inc Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer
ES2812336T3 (es) * 2016-03-03 2021-03-16 Shenzhen Targetrx Inc Macrocíclico y composición que comprende el mismo
CN106008531B (zh) * 2016-05-30 2019-01-11 上海交通大学 多环稠合大环内酰胺类化合物的抗胰腺癌用途
TW201815799A (zh) 2016-07-28 2018-05-01 美商Ｔｐ生物醫藥公司 巨環激酶抑制劑
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
BR112020001695A2 (pt) 2017-07-28 2020-07-21 Turning Point Therapeutics, Inc. compostos macrocíclicos e usos dos mesmos
IL295978B2 (en) 2017-10-18 2024-01-01 Incyte Corp Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
GB201721235D0 (en) 2017-12-19 2018-01-31 Syngenta Participations Ag Polymorphs
CN111511746B (zh) * 2017-12-19 2024-01-09 特普医药公司 用于治疗疾病的巨环化合物
US20210087206A1 (en) * 2017-12-19 2021-03-25 Turning Point Therapeutics, Inc. Macrocyclic kinase inhibitors and their use
US10662172B2 (en) 2017-12-19 2020-05-26 Bristol-Myers Squibb Company Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
WO2019120267A1 (zh) 2017-12-22 2019-06-27 成都先导药物开发股份有限公司 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂
WO2019201282A1 (zh) 2018-04-18 2019-10-24 成都先导药物开发股份有限公司 一种大环类激酶抑制剂

Also Published As

Publication number Publication date
JOP20200152A1 (ar) 2022-10-30
SMT202200443T1 (it) 2023-01-13
IL275265B2 (en) 2023-07-01
PT3728271T (pt) 2022-10-06
US11286265B2 (en) 2022-03-29
CN111511746B (zh) 2024-01-09
SG11202005590PA (en) 2020-07-29
CL2020001632A1 (es) 2020-11-20
US20220306652A1 (en) 2022-09-29
SI3728271T1 (sl) 2023-01-31
IL275265B1 (en) 2023-03-01
US10745416B2 (en) 2020-08-18
US20200190110A1 (en) 2020-06-18
JP7194188B2 (ja) 2022-12-21
PH12020550901A1 (en) 2021-05-17
KR102814342B1 (ko) 2025-05-29
EP3728271B1 (en) 2022-09-28
ES2929467T3 (es) 2022-11-29
AU2018392332A1 (en) 2020-06-11
LT3728271T (lt) 2022-12-12
RS63787B1 (sr) 2022-12-30
HRP20221502T1 (hr) 2023-03-31
MX2020006490A (es) 2020-08-17
PE20200937A1 (es) 2020-09-17
PL3728271T3 (pl) 2023-01-23
IL275265A (en) 2020-07-30
JP2023027237A (ja) 2023-03-01
EP3728271A4 (en) 2021-06-23
WO2019126121A1 (en) 2019-06-27
CA3083674A1 (en) 2019-06-27
EP4151641A1 (en) 2023-03-22
US20200392160A1 (en) 2020-12-17
BR112020012319A2 (pt) 2020-11-24
JP2021506850A (ja) 2021-02-22
KR20200101358A (ko) 2020-08-27
HUE060711T2 (hu) 2023-04-28
EP3728271A1 (en) 2020-10-28
TW201930312A (zh) 2019-08-01
DK3728271T3 (da) 2022-12-19
AU2018392332B2 (en) 2023-08-03
CN111511746A (zh) 2020-08-07

Similar Documents

Publication Publication Date Title
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
MX2023001876A (es) Derivados de rapamicina.
CO2020000633A2 (es) Compuestos macrocíclicos y usos de los mismos
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2017011484A2 (es) Inhibidores de bromodominio
MX2020001360A (es) Macrociclos de diarilo como moduladores de la proteina quinasa.
BR112016023558A2 (pt) compostos úteis como imunomoduladores
UY33883A (es) Novedosos derivados heterocíclicos
MX2021006734A (es) Metodo para tratar el cancer.
CL2017003067A1 (es) Piridinas sustituidas y método de uso
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
CR20170157A (es) Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
MX2018013701A (es) Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3.
ECSP18056196A (es) Derivados de indano
CR20150641U (es) Composiciones farmacéuticas
MX2020004871A (es) Derivados de acido cafeico y sus usos.